Academic Journal
HSA-Binding Prodrugs-Based Nanoparticles Endowed with Chemo and Photo-Toxicity against Breast Cancer
| العنوان: | HSA-Binding Prodrugs-Based Nanoparticles Endowed with Chemo and Photo-Toxicity against Breast Cancer |
|---|---|
| المؤلفون: | Rapozzi V., Moret F., Menilli L., Guerrini A., Tedesco D., Naldi M., Bartolini M., Gani M., Zorzet S., Columbaro M., Milani C., Martini C., Ferroni C., Varchi G. |
| المساهمون: | Rapozzi, V., Moret, F., Menilli, L., Guerrini, A., Tedesco, D., Naldi, M., Bartolini, M., Gani, M., Zorzet, S., Columbaro, M., Milani, C., Martini, C., Ferroni, C., Varchi, G. |
| سنة النشر: | 2022 |
| المجموعة: | Università degli Studi di Udine: CINECA IRIS |
| مصطلحات موضوعية: | Albuminbinding, Breast cancer, Combination therapy, Nanoparticle, Paclitaxel, Pheophorbide a, Prodrugs |
| الوصف: | Exploiting the tumor environment features (EPR effect, elevated glutathione, reactive oxygen species levels) might allow attaining a selective and responsive carrier capable of improving the therapeutic outcome. To this purpose, the in situ covalent binding of drugs and nanoparticles to circulating human serum albumin (HSA) might represent a pioneering approach to achieve an effective strategy. This study describes the synthesis, in vitro and in vivo evaluation of bioresponsive HSA-binding nanoparticles (MAL-PTX2 S@Pba), co-delivering two different paclitaxel (PTX) prodrugs and the photosensitizer pheophorbide a (Pba), for the combined photo-and chemo-treatment of breast cancer. Stable and reproducible MAL-PTX2 S@Pba nanoparticles with an average diameter of 82 nm and a PTX/Pba molar ratio of 2.5 were obtained by nanoprecipitation. The in vitro 2D combination experiments revealed that MAL-PTX2 S@Pba treatment induces a strong inhibition of cell viability of MDA-MB-231, MCF7 and 4T1 cell lines, whereas 3D experiments displayed different trends: while MAL-PTX2 S@Pba effectiveness was confirmed against MDA-MB-231 spheroids, the 4T1 model exhibited marked resistance. Lastly, despite using a low PTX-PDT regimen (e.g., 8.16 mg/Kg PTX and 2.34 mg/Kg Pba), our formulation showed to foster primary tumor reduction and curb lung metastases growth in 4T1 tumor-bearing mice, thus setting the basis for further preclinical validations. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | volume:14; issue:4; firstpage:877; journal:CANCERS; http://hdl.handle.net/11390/1221668; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85124206642 |
| DOI: | 10.3390/cancers14040877 |
| الاتاحة: | http://hdl.handle.net/11390/1221668 https://doi.org/10.3390/cancers14040877 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.60C01720 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers14040877 |
|---|